Prevalence and factors associated with carriage of Pfmdr1 polymorphisms among pregnant women receiving intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) and artemether-lumefantrine for malaria treatment in Burkina Faso

Table 5 Univariate and multivariable analyses assessing factors associated with pfmdr1 N86Y mutant allele at delivery

Variables	N	OR (95%CI)	P	AOR (95%CI)	P
Parasite density	116
< Median (2,237.2 parasites/µl)	43	1
≥ Median	73	4.03 (0.86–19.0)	0.08	5.5 (1.07–28.0)	0.04
Number of SP doses	116
< 3	78	1
≥ 3	38	0.13 (0.02–1.07)	0.06	0.25 (0.07–0.92)	0.04
MiP preventive strategy	116
IPTp-SP	56	1
CSST/IPTp-SP	60	0.92 (0.30–2.83)	0.89
Triple dhfr 51/59/108 mutation
No	25	1
Yes	58	1.64 (0.30–8.95)	0.57
AL treatment during pregnancy
0	51	1
≥ 1	65	0.39 (0.12–1.24)	0.10	0.25 (0.07–0.89)	0.03
Timing Al treatment to delivery
No treatment	51	1
4 to 28 days	20	0.51 (0.10–2.64)	0.43
29 to 42 days	21	0.001 (0.001–1.01)	0.96
43 to 63 days	13	0.39 (0.04–3.38)	0.39
≥ 64 days	11	1.04 (0.19–5.64)	0.97
Age	116
< Mean (25.2 years ± 6.4	58	1
≥ Median	58	0.88 (0.28–2.71)	0.82
Gravidity	116
Primi-secundigravidae	55	1
Multigravidae	61	0.64 (0.21–1.98)	0.44
Malaria episode	116
< 2	37	1
≥ 2	79	0.82 (0.25–2.65)	0.74
Malaria infection at ANC-1 and at delivery
No	85	1
Yes	31	1.62 (0.50–5.28)	0.42
Haemoglobin level at delivery	113
≥ Mean 11.5 g/dl ± 1.7	55	1
< Mean	58	0.68 (0.22–2.10)	0.50
ITN usage	101
No	34	1
Yes	67	0.46 (0.13–1.55)	0.21

ISSN: 1475-2875